Arvaya Healthcare Limited has scheduled a Board of Directors meeting for August 26, 2026, to consider the acquisition of the business undertaking of Navahmedi Solution Private Limited. The proposed transaction involves a slump sale covering intellectual property, assets, and liabilities.

The company intends to fund this related party transaction using proceeds from its rights issue. This strategic move aims to expand Arvaya’s operational footprint through asset acquisition rather than organic growth in the immediate term.

Transaction Details

The board agenda specifically includes the approval of the related party transaction with Navahmedi Solution Private Limited. The structure of the deal is defined as a slump sale, which allows for the transfer of the entire business unit as a going concern.

Regulatory Compliance

Arvaya Healthcare Limited issued this intimation pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was filed with the Bombay Stock Exchange Listing Department on August 21, 2026.

Kaushal Shah, Managing Director of the company, signed the intimation. The company, formerly known as Bijoy Hans Limited, operates under ISIN INE491D01017.

Shareholders of Arvaya Healthcare Limited have approved a slate of strategic and administrative resolutions through a postal ballot process that concluded on August 13, 2026. The most significant outcome was the approval of the acquisition of Sushodha Institute of Gastroenterology Private Limited, executed through a preferential issue of equity shares for consideration other than cash.

The company, formerly known as Bijoy Hans Limited, also secured shareholder consent to shift its registered office from Assam to Maharashtra and to regularize the appointment of Mr. Bidari Kotresh Anilkumar as Executive Director. All six resolutions on the ballot were passed with unanimous support from those who voted.

Voting Breakdown and Resolution Details

The postal ballot was scrutinized by Mr. Chinmay Mohan Lele, a Company Secretary, whose report was issued on August 14, 2026. As of the record date of July 10, 2026, the company had 3,416 shareholders. The total outstanding shares stood at 48,021,857.

Voting participation varied across resolutions. For the acquisition-related resolutions, public non-institutional shareholders polled 51.19% of their held shares. In contrast, participation for the name change and registered office shift resolutions was higher at 56.35% among the same group. Promoter and promoter group entities, holding 14,703,679 shares, voted in full (100%) on all resolutions except the related-party transaction, where they abstained as required.

What the Numbers Show

A key structural observation from the voting data is the complete abstention of promoter group votes on the special resolution concerning the acquisition of Sushodha Institute of Gastroenterology Private Limited. While promoters hold 14,703,679 shares, they cast zero votes on this specific agenda item, likely due to conflict of interest rules given their declared interest in the related-party transaction. Consequently, the entire burden of approval fell on public non-institutional shareholders, who voted 17,054,742 shares in favor with zero votes against. This indicates strong minority shareholder support for the deal despite the promoters' recusal.

Additionally, no institutional investors participated in the voting, as the "Public-Institutions" category showed zero shares held and zero votes polled across all resolutions. This suggests the company's institutional investor base may be minimal or entirely absent from the register as of the record date.